Calviri is an early stage healthcare company whose mission is to provide a broad spectrum of fundamentally different vaccines and companion diagnostics that prevent and treat cancer for those either at risk or diagnosed. Calviri is focused on using frameshift neoantigens derived from errors in RNA processing to provide pioneering products against cancer.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/02/20 | $2,250,000 | Seed |
Dr. Jacque Sokolov Dr. Mitzi Krockover | undisclosed |
